IN2014KN02672A - - Google Patents

Info

Publication number
IN2014KN02672A
IN2014KN02672A IN2672KON2014A IN2014KN02672A IN 2014KN02672 A IN2014KN02672 A IN 2014KN02672A IN 2672KON2014 A IN2672KON2014 A IN 2672KON2014A IN 2014KN02672 A IN2014KN02672 A IN 2014KN02672A
Authority
IN
India
Prior art keywords
mammal
csf
ependymal cells
apoe
protective
Prior art date
Application number
Other languages
English (en)
Inventor
Beverly L Davidson
Bradley T Hyman
Original Assignee
Univ Iowa Res Found
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Iowa Res Found, Gen Hospital Corp filed Critical Univ Iowa Res Found
Publication of IN2014KN02672A publication Critical patent/IN2014KN02672A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IN2672KON2014 2012-05-18 2013-03-14 IN2014KN02672A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261648801P 2012-05-18 2012-05-18
PCT/US2013/031725 WO2013172964A1 (fr) 2012-05-18 2013-03-14 Procédés et compositions de traitement de dépôts amyloïdes

Publications (1)

Publication Number Publication Date
IN2014KN02672A true IN2014KN02672A (fr) 2015-05-08

Family

ID=49584137

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2672KON2014 IN2014KN02672A (fr) 2012-05-18 2013-03-14

Country Status (12)

Country Link
US (1) US20150183850A1 (fr)
EP (1) EP2850195B1 (fr)
JP (2) JP6469000B2 (fr)
CN (2) CN104540952A (fr)
AU (1) AU2013263346B2 (fr)
BR (1) BR112014028666B1 (fr)
CA (1) CA2873890C (fr)
ES (1) ES2786078T3 (fr)
HK (1) HK1207109A1 (fr)
IN (1) IN2014KN02672A (fr)
RU (1) RU2673484C2 (fr)
WO (1) WO2013172964A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230145206A (ko) 2014-11-14 2023-10-17 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
WO2016196507A1 (fr) 2015-05-29 2016-12-08 University Of Iowa Research Foundation Méthodes d'administration de transgènes pour le traitement de maladies cérébrales
EP3307391A1 (fr) * 2015-06-12 2018-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et composition pharmaceutique pour le traitement de la maladie d'alzheimer
KR20180134373A (ko) * 2016-04-14 2018-12-18 타오 헬스 라이프 파마 가부시키가이샤 아밀로스페로이드(aspd)형 구조체 및 의약 조성물
US10584337B2 (en) 2016-05-18 2020-03-10 Voyager Therapeutics, Inc. Modulatory polynucleotides
CN109715194B (zh) * 2016-08-03 2024-06-11 南佛罗里达大学 用于治疗神经障碍的颤蛋白组合物
WO2018045347A1 (fr) * 2016-09-02 2018-03-08 Spark Therapeutics, Inc. Procédés et vecteurs destinés au traitement de troubles du snc
EP3309550A1 (fr) * 2016-10-12 2018-04-18 sphingotec GmbH Procédé pour la détection de l'apolipoprotéine e4
EP3692158A4 (fr) 2017-10-03 2021-08-04 Prevail Therapeutics, Inc. Thérapies géniques pour troubles lysosomiaux
MX2020004005A (es) 2017-10-03 2020-10-05 Prevail Therapeutics Inc Terapias genicas para los trastornos lisosomales.
CA3121211A1 (fr) * 2018-11-28 2020-06-04 Prevail Therapeutics, Inc. Therapies geniques pour maladie neurodegenerative
JP2023500793A (ja) * 2019-10-16 2023-01-11 コーネル・ユニバーシティー アルツハイマー病に対する遺伝子治療方法
KR20220107243A (ko) 2019-11-25 2022-08-02 코넬 유니버시티 Apoe 유전자 요법
EP4130014A4 (fr) * 2020-03-31 2024-05-15 Nuo-Beta Pharmaceutical Technology (Shanghai) Co., Ltd. Composé d'oxophénylarsine deutéré et son utilisation
KR20230112672A (ko) * 2020-11-25 2023-07-27 프리베일 테라퓨틱스, 인크. 신경변성 질환을 위한 유전자 요법
CN120187407A (zh) * 2021-12-15 2025-06-20 健达九州(北京)生物科技有限公司 重组aav载体及其用途
CN116063405B (zh) * 2022-09-27 2025-08-29 广州译码基因科技有限公司 可提高AAV病毒包装能力的衣壳蛋白突变体MutC及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589154A (en) * 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
US6436996B1 (en) * 1997-09-30 2002-08-20 Duke University Modulation of nitric oxide production
US6468524B1 (en) 2000-03-22 2002-10-22 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services AAV4 vector and uses thereof
US6855314B1 (en) 2000-03-22 2005-02-15 The United States Of America As Represented By The Department Of Health And Human Services AAV5 vector for transducing brain cells and lung cells
GB0322645D0 (en) * 2003-09-26 2003-10-29 Melacure Therapeutics Ab Use of antisecretory factor peptides
EP1828390B1 (fr) * 2004-12-15 2012-06-13 The University Of North Carolina At Chapel Hill Vecteurs chimeriques
AU2006242129A1 (en) * 2005-05-02 2006-11-09 Genzyme Corporation Gene therapy for spinal cord disorders
JP2010504909A (ja) * 2006-09-14 2010-02-18 メドジェニクス・メディカル・イスラエル・リミテッド 長期持続性の医薬製剤
CN104383556B (zh) * 2007-05-16 2018-06-05 布里格姆妇女医院 突触核蛋白病的治疗
CA2833912C (fr) * 2010-04-23 2021-09-21 University Of Massachusetts Traitement a base d'aav pour des troubles lies au cholesterol

Also Published As

Publication number Publication date
WO2013172964A1 (fr) 2013-11-21
US20150183850A1 (en) 2015-07-02
JP2015520161A (ja) 2015-07-16
RU2673484C2 (ru) 2018-11-27
CA2873890C (fr) 2022-12-06
EP2850195B1 (fr) 2020-01-22
HK1207109A1 (en) 2016-01-22
ES2786078T3 (es) 2020-10-08
CN104540952A (zh) 2015-04-22
BR112014028666B1 (pt) 2021-12-07
CA2873890A1 (fr) 2013-11-21
AU2013263346A1 (en) 2014-12-04
JP2019031564A (ja) 2019-02-28
AU2013263346B2 (en) 2018-08-23
EP2850195A4 (fr) 2015-12-09
BR112014028666A2 (pt) 2017-06-27
JP6469000B2 (ja) 2019-02-13
CN112574964A (zh) 2021-03-30
RU2014151218A (ru) 2016-07-10
EP2850195A1 (fr) 2015-03-25

Similar Documents

Publication Publication Date Title
HK1207109A1 (en) Methods and compositions for treating amyloid deposits
CA2832151C (fr) Procedes et compositions pour traiter des maladies cerebrales
MX2023007728A (es) Composiciones para el tratamiento de esclerosis lateral amiotrofica (ela).
MX363533B (es) Proteínas de fusión que comprenden partes de unión a pdgf y vegf y métodos de uso de las mismas.
WO2015013148A3 (fr) Procédés et compositions pour traiter des maladies du cerveau
PH12017501436A1 (en) Enhanced delivery of viral particles to the striatum and cortex
WO2015109124A3 (fr) Agents immunomodulateurs
PH12018501055A1 (en) Cpg reduced factor viii variants, compositions and methods and uses for treatment of hemostasis disorders
MX365711B (es) Administración efectiva de genes grandes por vectores aav duales.
EP4219727A3 (fr) Produits et procédés pour le traitement de la sclérose latérale amyotrophique
MX2017014125A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
PH12014502274B1 (en) Anti-fcrn antibodies
MX351762B (es) Variantes de glucoamilasas y polinucleotidos que las codifican.
WO2015014790A3 (fr) Variants de protéase et polynucléotides les codant
MX2015016814A (es) Anticuerpo anti-tweakr y sus usos.
MX2014004598A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
MX351154B (es) Variantes de glucoamilasas y polinucleotidos que las codifican.
MX371018B (es) Polipéptidos que tienen actividad de transgalactosilación.
EP2561073A4 (fr) Vecteurs aav ciblant le système nerveux central et leurs procédés d'utilisation
MX2014004539A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
WO2013006756A3 (fr) Variants d'alpha-amylase et polynucléotides codant ces variants
MX2021013104A (es) Variantes de lipasa y polinucleotidos que las codifican.
WO2013163590A3 (fr) Variants du polypeptide gh61 et polynucléotides codant pour ceux-ci
WO2014195356A3 (fr) Variants d'alpha-amylase et polynucléotides les codant
EA201691004A1 (ru) Последовательность модифицированного эндолизина kz144